MVA-BN is approved in Canada (marketed under the trade name IMVAMUNE®) and in the European Union (marketed under the trade name IMVANEX®. Phase 3 registration trials have been successfully concluded in the U.S. and a BLA was filed with the FDA in October 2018.

MVA-BN is a non-replicating smallpox vaccine distributed in liquid-frozen formulation, suitable for use in people for whom replicating smallpox vaccines are contraindicated (e.g. people with HIV and atopic dermatitis). The vaccine is the only non-replicating smallpox vaccine approved in Europe for use in the general adult population. Although not yet approved in the United States, MVA-BN is currently stockpiled by the U.S. Government for emergency use in people for whom replicating smallpox vaccines are contraindicated. Registration studies to support FDA approval for use of the vaccine in the entire population have been concluded and a BLA was submitted in October 2018.

Traditional smallpox vaccines are based on replicating vaccinia virus strains. Although these vaccines have been effective in preventing the disease, their use may be associated with an increased risk of adverse events, including death and severe disability.

MVA-BN is injected like other modern vaccines rather than pricked into the skin with a bifurcated needle. While the MVA-BN virus is highly attenuated and is thus incapable of replicating in the body, it is still capable of eliciting a potent immune response and does so without producing the post-vaccination complications associated with traditional smallpox vaccines.

Although the World Health Organization (WHO) declared smallpox eradicated in 1980, this contagious and deadly disease remains high on the list of possible bioterror threats. Unique to humans, the disease is caused by the Variola virus and transmitted from person to person through direct contact with contaminated fluids and objects, as well as through the air. Historically, about 30% of those who became infected with smallpox died from the illness. There is currently no cure for the disease, vaccination is the only proven protection.

The U.S. government considers smallpox a material threat to national security. National security concerns are based on intelligence regarding previous biological weapons programs, coupled with the infectivity of the virus, an increasingly vulnerable population due to lack of immunity, and the relative ease of large-scale production. In fact, the U.S. Department of Defense has a mandatory smallpox vaccination program for troops being deployed to certain areas around the globe.

While the only known samples of smallpox are held at secure labs in the U.S. and Russia, the U.S. National Research Council found in a 2008 report that "the creation or acquisition of smallpox is well within the technical reach of a determined and well-resourced terrorist."

Given today's global travel and the virus' long incubation period, all nations must safe-guard against this virus. A smallpox outbreak anywhere could quickly become a global, not a local, problem.

Overton ET, Lawrence SJ, Wagner E, Nopora K, Rösch S, Young P, et al.
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

PLoS ONE. 2018 13(4): e0195897. doi:10.1371/journal.pone.0195897

Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, et al.
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects

PLoS ONE. 2016 11(6): e0157335. doi:10.1371/journal.pone.0157335

Greenberg RN, Hurley Y, Dinh DV, Mraz S, Vera JG, von Bredow D, et al.
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis

PLoS ONE. 2015 10(10): e0138348. doi:10.1371/journal.pone.0138348

Zitzmann-Roth E-M, von Sonnenburg F, de la Motte S, Arndtz-Wiedemann N, von Krempelhuber A, Uebler N, et al.
Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population

PLoS ONE. 2015 10(4):e0122653. doi:10.1371/journal.pone.0122653

Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, Wagner E, von Krempelhuber A, Virgin G, Meyer TP, Müller J, Bädeker N, Grünert R, Young P, Rösch S, Maclennan J, Arndtz-Wiedemann N, Chaplin P.
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.

Open Forum Infect Dis. 2015 May 5;2(2):ofv040. doi: 10.1093/ofid/ofv040.

von Sonnenburg F, Perona P, Darsow U, Ring J, von Krempelhuber A, Vollmar J, Roesch S, Baedeker N, Kollaritsch H, Chaplin P
Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis

Vaccine. 2014 Sep 29;32(43):5696-702. doi: 10.1016/j.vaccine.2014.08.022. Epub 2014 Aug 20.

Frey SE, Winokur PL . et al.
Safety and immunogenicity of IMVAMUNE(®) smallpox vaccine using different strategies for a post event scenario

Vaccine. 2013 Jun 24;31(29):3025-33. doi: 10.1016/j.vaccine.2013.04.050.

Hatch GJ, Graham VA, et al.
Assessment of the Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in Cynomolgus Macaques.

J Virol. 2013 Jul;87(14):7805-15. doi: 10.1128/JVI.03481-12.

Townsend MB, Keckler MS, et al.
Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.

J Virol. 2013 Jan;87(2):900-11. doi: 10.1128/JVI.02089-12.

Walsh SR, Wilck MB, et al.
Safety and immunogenicity of modified vaccinia ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

J Infect Dis. 2013 Jun 15;207(12):1888-97. doi: 10.1093/infdis/jit105.

Keckler MS, Carroll DS, et al.
Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.

J Virol. 2011 Aug;85(15):7683-98. doi: 10.1128/JVI.02174-10.

von Krempelhuber A, Vollmar J, et al.
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Vaccine. 2010 Feb 3;28(5):1209-16. doi: 10.1016/j.vaccine.2009.11.030.

Wolff MW, Siewert C, et al.
Capturing of cell culture-derived modified Vaccinia Ankara virus by ion exchange and pseudo-affinity membrane adsorbers.

Biotechnol Bioeng. 2010 Mar 1;105(4):761-9. doi: 10.1002/bit.22595.

Garza NL, Hatkin JM, et al.
Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.

Vaccine. 2009 Sep 4;27(40):5496-504. doi: 10.1016/j.vaccine.2009.06.105.

Kennedy JS, Greenberg RN
IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine

Expert Rev Vaccines. 2009 Jan;8(1):13-24. doi: 10.1586/14760584.8.1.13.

Sano J, Chaitman BR, et al.
Electrocardiography screening for cardiotoxicity after modified Vaccinia Ankara vaccination.

Am J Med. 2009 Jan;122(1):79-84. doi: 10.1016/j.amjmed.2008.07.025.

Jones T
IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.

Curr Opin Mol Ther. 2008 Aug;10(4):407-17.

Frey SE, Newman FK, et al.
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.

Vaccine. 2007 Dec 12;25(51):8562-73.

Vollmar J, Arndtz N, et al.
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.

Vaccine. 2006 Mar 15;24(12):2065-70.